Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02221726 · ClinicalTrials.gov registry record · Early Phase 1
Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults
A Early Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02221726 is a Early Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 16 participants.
The verdict
NCT02221726, a Early Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess 3 different scoring systems to evaluate the adhesive quality of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial\]) JNJ-35685-AAA-G-023-G transdermal (through the skin) systems during a single system 72-hour application, replicated 3 times, of 2 patch sizes (5.5 centimeter\^2 \[cm\^2\] and 44 cm\^2).
Interventions
- DRUG JNJ-35684-AAA-023: Size 1; small patch
- DRUG JNJ-35684-AAA-023: Size 2; large patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2014-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02221726
The ClinicalTrials.gov registry entry for NCT02221726 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-35684-AAA-023: Size 1; small patch is the first listed.
NCT02221726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02221726 about?
NCT02221726 is a clinical study titled "Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults". The purpose of this study is to assess 3 different scoring systems to evaluate the adhesive quality of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial\]) JNJ-35685-AAA-G-023-G transdermal (through the skin) systems during a s...
What is the current status of trial NCT02221726?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02221726?
The interventions under investigation include: JNJ-35684-AAA-023: Size 1; small patch (DRUG), JNJ-35684-AAA-023: Size 2; large patch (DRUG).
Who is sponsoring clinical trial NCT02221726?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.